Paxil Late-Listed Patents Are Questionable For Orange Book Listing – FTC
Executive Summary
Generic versions of Paxil are being held up by patents whose listing in the "Orange Book" is questionable, the Federal Trade Commission's generic drug report states
You may also be interested in...
AstraZeneca Fined $72 Mil. In Europe For Blocking Omeprazole Generic
AstraZeneca delayed market entry of omeprazole generics in Europe by supplying misleading patent information and deregistering the capsule formulation of its proton pump inhibitor Losec in certain countries, the European Commission said June 15
AstraZeneca Fined $72 Mil. In Europe For Blocking Omeprazole Generic
AstraZeneca delayed market entry of omeprazole generics in Europe by supplying misleading patent information and deregistering the capsule formulation of its proton pump inhibitor Losec in certain countries, the European Commission said June 15
“Authorized” Generics Are “Legitimate Business Strategy,” Pfizer Says
Pfizer views "authorized" generics as a sound business strategy following a drug's patent expiration, Senior Corporate Counsel Jeffrey Chasnow said during a Drug & Device Dialogue audio conference Oct. 7